Shots:

• ADC to receive a $30M up front & is eligible to receive ~$205M upon achievement of development & commercial milestones along with royalties on net sales of the product
• MTPC to get the rights to take part in any global clinical studies of the product by bearing a portion of the costs of the study & will be responsible to conduct clinical studies of Zynlonta in Japan
• Zynlonta is the 1st CD19-targeted ADC & has received accelerated approval from the US FDA for adult patients with r/r DLBCL after 2 or more lines of systemic therapy. The therapy has received ODD in the EU for DLBC & is being evaluated as a therapeutic option in combination studies in other B-cell malignancies

Ref: Businesswire | Image: ADC